Arrakis Therapeutics Announces CEO Transition with Mark DeLong Appointed as New CEO
Mark DeLong to lead Arrakis as it becomes a clinical-stage company, advancing its lead oral RNA-targeted small molecule to treat myotonic dystrophy type 1 (DM1) Michael Gilman retires from role of CEO following distinguished 40-year career in biotech Katrine Bosley transitions the role of Chairman of the Arrakis Board of Directors to Michael Gilman, and […]